Replies to post #213350 on Biotech Values

[DewDiligence]

Kymriah price for pediatric ALL=$475K—with 1-month warranty:

https://www.forbes.com/sites/matthewherper/2017/08/30/novartis-ceos-dilemma-is-475000-too-much-for-a-leukemia-breakthrough-or-is-it-not-enough/#36e1d20d556e

If it were up to me, the price would be higher, but the warranty would be much longer—perhaps six months instead of one month.

[DewDiligence]

Kymriah”s outcomes-based pricing remains—despite CMS objection:

https://www.biocentury.com/bc-extra/politics-policy/2018-07-09/kymriah-deal-stay-despite-cms-shift-proposed-pilot